Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EMD Lexigen Research Center

Division of Merck KGaA

Latest From EMD Lexigen Research Center

Synta Pharmaceuticals Corp.

Synta Pharmaceuticals Corp. isn't a traditional emerging biotech company. In fact, the firm is bucking many industry trends-it raised none of its $180 million from venture capitalists, developed each of its existing three drug candidates internally, and owns all the rights to its compounds. Further, notes Synta's co-founder, president and CEO, Safi Bahcall, PhD, the company has a productive, systems-driven drug discovery platform that will continue to feed its product pipeline.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Lexigen Pharmaceuticals Corp.
  • Fuji ImmunoPharm
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Merck KGaA
  • Senior Management
  • Stephen D Gillies, Pres. & CEO
    Kin-Min Lo, VP, Research
  • Contact Info
  • EMD Lexigen Research Center
    Phone: (978) 294-1100
    Bedford Campus, 45A Middlesex Turnpike
    Billerica, MA 01821